Background: Alopecia areata is a common and unpleasant illness that manifests as abrupt, circular patches of complete hair loss that heal scar-free. For most individuals with patchy alopecia areata, intralesional or topical corticosteroids are regarded the first therapeutic option due to their relative safety and convenience; nevertheless, there is limited evidence for their efficacy. Objective: Review of the literature on New Treatment Strategies in Management of Alopecia Areata. Methods: We looked for data on New Treatment Strategies and Alopecia Areata, treatment in medical journals and databases like PubMed, Google Scholar, and Science Direct. However, only the most recent or extensive study was taken into account between November 2002 and December 2021. References from related works were also evaluated by the writers. There are not enough resources to translate documents into languages other than English, hence those documents have been ignored. It was generally agreed that documents such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations did not qualify as legitimate scientific study. Conclusion: When a ligand attaches to their specific cytokine receptor, janus kinases (JAKs) can phosphorylate signal transducers and activators of transcription (STATs). Hair regrowth is facilitated by oral formulations because they are simple to ingest. Tofacitinib comes in 5-mg and 11-mg doses and can be taken once or twice day. Treatment options for alopecia areata of the scalp are limited, but the 308-nm excimer laser has proven to be helpful in restoring hair growth in affected areas.